Posted: 20 Aug 2011 05:03 PM PDT
Once again, thank you for all of the emails I received with contact information for amyloidosis specialists that I could pass along to Bill and Diane. The response was overwhelming!
I don't know if you realize my blog is averaging around 1000 readers per day. That's quite a lot for a site as specialized as this one. Our readership is exceptionally well informed, so I wasn't surprised when the emails came pouring in.
Speaking of emails. I get hundreds every day. I spend an our or two sifting through them--and I try to answer the ones from patients, caregivers and their friends and families as soon as I can.
But it's all worth it, especially when I get an email like this one about clinical trials from the Multiple Myeloma Research Foundation (MMRF):
The elotuzumab and panobinostat studies interest me most. Most of you have probably heard of carfilzomib. But these other two are the most promising anti-myeloma assisting type drugs undergoing advanced clinical trials at this time.
By "assisting type drugs," I mean that while neither of these drugs work especially well by themselves against multiple myeloma, they do seem to work exceptionally well when combined with Revlimid or Velcade. So well that early studies indicate the new combinations allow the Revlimid or Velcade to work again, even if a patient's myeloma has become resistant (refractory) to the main drug alone.
Pretty cool, right! I believe drug combo's using new assisting drugs like these are the future of myeloma therapy. So do a lot of myeloma researchers and specialists.
I will write a bit more about the importance of developing as many assisting drugs like these as possible tomorrow.
Until then, feel good and keep smiling! Pat
|You are subscribed to email updates from Multiple Myeloma Blog |
To stop receiving these emails, you may unsubscribe now.
|Email delivery powered by Google|
|Google Inc., 20 West Kinzie, Chicago IL USA 60610|